Jeffrey Chodakewitz Buys Shares of ACET $ACET
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jeffrey Chodakewitz, insider at Adicet Bio, Inc. ($ACET), bought 4,200 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Adicet Bio, Inc. Stock Down 8.4%
Shares of Adicet Bio, Inc. ($ACET) traded around $8.30 on Wednesday, down 8.4% for the day.
Adicet Bio, Inc. Earnings
Analysts Set New Price Targets
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Get Adicet Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ACET, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.